Symphogen announced that Jesper Bramming has joined as its new Chief Financial Officer, filling the position vacated by Martin Olin, M.Sc., EMBA, who was promoted to Chief Executive Officer and member of the Board of Directors.
Jesper Bramming comes to Symphogen from the CMC Biologics Group where he was Chief Financial Officer and a member of the Group Management Team. His responsibilities included financial accounting and reporting, legal and IT. Prior to CMC Biologics, Bramming was Executive Vice President and Chief Financial Officer with Nets Holding A/S . Prior to that, for sixteen years, he held financial management level positions within the A.P: Møller-Maersk Group and was Chief Financial Officer of Svitzer A/S. Prior to these assignments, Bramming held a number of senior positions in banking and investment management in leading European firms. He holds Board seats as Chairman of both Menu A/S Scandinavia Living A/S and Rejsekort A/S, and is a director of Danske Invest Management. He holds a Master of Economics from the University of Copenhagen, and is an alumni of Columbia University’s Senior Executive Management Program. He is also a Chartered Financial Analyst.
Chief Executive Officer, Martin Olin, commented: “Jesper brings to Symphogen his extensive experience at one of the top international companies in Denmark, and more recently, expertise in the healthcare sector from CMC Biologics, now one of the world’s leading contract manufacturing businesses. His success in both multi-national finance, healthcare experience and investment banking background uniquely positions him to be part of Symphogen as we mature our proprietary portfolio and explore strategic opportunities.”